Inhibition of eEF-2 kinase sensitizes human nasopharyngeal carcinoma cells to lapatinib-induced apoptosis through the Src and Erk pathways by Lin Liu et al.
RESEARCH ARTICLE Open Access
Inhibition of eEF-2 kinase sensitizes human
nasopharyngeal carcinoma cells to
lapatinib-induced apoptosis through the
Src and Erk pathways
Lin Liu1†, PeiYu Huang2†, ZhiHui Wang1†, Nan Chen1, Con Tang3, Zhong Lin1 and PeiJian Peng1*
Abstract
Background: Previous studies have reported that eEF-2 kinase is associated with tumour cell sensitivity to certain
therapies. In the present study, we investigated the relationship between eEF-2 kinase and lapatinib, a dual inhibitor
of EGFR and HER-2, in nasopharyngeal carcinoma (NPC) cells.
Methods: The effect of treatment on the growth and proliferation of NPC cells was measured by three methods:
cell counting, crystal violet staining and colony counting. Apoptosis was evaluated by flow cytometry to determine
Annexin V-APC/7-AAD and cleaved PARP levels, and the results were further confirmed by Western blot analysis.
The expression of eEF-2 kinase and the impacts of different treatments on different signalling pathways were
analysed by Western blot analysis.
Results: The expression of eEF-2 kinase was significantly associated with NPC cell sensitivity to lapatinib. Therefore,
suppression of this kinase could increase the cytocidal effect of lapatinib, as well as reduce cell viability and colony
formation. Furthermore, inhibition of eEF-2 kinase, by either RNA interference (eEF-2 kinase siRNA or shRNA) or
pharmacological inhibition (NH125), enhanced lapatinib-induced apoptosis of NPC cells. The results also showed
that lapatinib combined with NH125 had a synergistic effect in NPC cells. In addition, mechanistic analyses revealed
that downregulation of the ERK1/2 and Src pathways, but not the AKT pathway, was involved in this sensitizing
effect.
Conclusions: The results of this study suggest that targeting eEF-2 kinase may improve the efficacy of therapeutic
interventions such as lapatinib in NPC cells.
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Background
Nasopharyngeal carcinoma (NPC) is a rare head and neck
cancer found worldwide, but with particular prevalence in
southern China and Southeast Asia [1]. The incidence of
NPC in high-incidence regions can reach 15–30 per
100,000 [2]. High rates of recurrence and metastasis are
the major reasons for poor prognosis. The most successful
therapies for NPC are a combination of radiation and
chemotherapy; however, the relapse rate for metastatic pa-
tients is as high as 82 % [3]. In addition, the side effects of
radical radiation severely impact quality of life. Therefore,
developing novel therapeutics for NPC, and especially
new target agents, is urgent.
The epidermal growth factor receptor (EGFR) signalling
pathway is highly correlated with invasion or metastasis of
NPC and therefore is indirectly related to poor survival
[4]. In endemic areas, both EGFR and HER-2 are co-
expressed in approximately 33-87 % of patients with NPC
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Lapatinib, also known as Tykerb or GW572016, is the
first dual tyrosine kinase inhibitor of EGFR and HER-2.
Using in vitro NPC models, recent studies have shown
that lapatinib also has anti-tumour activity in NPC and
inhibits the phosphorylation of both EGFR and HER-2
[1]. Furthermore, a series of preclinical and clinical
studies examined the effects of lapatinib in many solid
tumours, including breast, lung, hepatocellular and gas-
tric cancers [7–10]. Despite its promising effects, lapati-
nib has a half maximal inhibitory concentration (IC50)
in the micromolar range in insensitive cell lines [1].
Thus, methods to sensitize NPC to lapatinib are cur-
rently under investigation.
Eukaryotic elongation factor-2 kinase (eEF-2 kinase),
also known as Ca2+/calmodulin-dependent protein kinase
III, is a unique enzyme. It participates in the synthesis of
various proteins by phosphorylating its only known sub-
strate eEF-2, and it is upregulated in various malignancies
[11, 12]. More recently, a number of investigations have
reported that eEF-2 kinase can modulate the sensitivity of
malignant cells to many agents [13–17].
Since lapatinib has limited cytocidal efficacy, and eEF-2
kinase may regulate the sensitivity of tumour cells, we in-
vestigated the effect of eEF-2 kinase inhibition on NPC
sensitivity to lapatinib.
Methods
Cell lines and culture
Three human NPC cell lines CNE-2, HONE-1 and
C666-1 were generously supplied by the State Key La-
boratory of Oncology in South China, People’s Republic
of China. The cell lines were cultured in RPMI-1640
medium (Gibco BRL Co. Ltd.,USA) supplemented with
10,000 U/ml penicillin and 10 μg/ml streptomycin. For
CNE-2 and HONE-1 cells, 10 % foetal bovine serum
(FBS) (Gibco) was added, whereas C666-1 required
20 % FBS. Cells were incubated at 37 °C in humidified
5 % carbon dioxide and 95 % air.
Inhibitors
Lapatinib and NH125 were purchased from Selleck
Chemicals (HOU, TX, USA). Stock solutions (1 mM)
were prepared using dimethyl sulfoxide (DMSO) and
stored at –20 °C. The inhibitors were added to cells
using fresh culture medium, ensuring that the concen-
tration of DMSO in the final solution did not exceed
1 % (v/v).
Cell viability analysis
Briefly, CNE-2, HONE-1 (3.0 × 103/well) and C666-1
cells (1.5 × 104/well) were seeded in 96-well plates and
then incubated with different inhibitors at various dilu-
tions for 48 h. Cell viability was assessed using the Cell
Counting Kit-8 (CCK-8; Dojindo Co., Japan) following
the manufacturer’s instructions. Optical density (OD)
was read at 450 nm on an enzyme-linked immunosorb-
ent assay reader (SpectraMax M5; Molecular Devices,
Sunnyvale, CA, USA) after 1 to 4 h of incubation. The
viability of the DMSO-treated group (control group) was
set to 100 %. Viability was calculated as follows: Cell sur-
vival rate (%) = (OD value of treatment group/OD value
of control group) × 100 %.
Crystal violet assay
Cells were suspended at a density of 8.0 × 104/well, dis-
tributed into six-well plates and treated with lapatinib,
NH125 or their combination at the indicated concen-
trations for 48 h. Following fixation with 4 % parafor-
maldehyde, the cells were stained with a 1 % crystal
violet solution for 20 min and then photographed. The
growth-inhibitory effects of the agents were directly
proportional to the number of stained cells.
Colony formation assay
Tumour cells were seeded into six-well plates at a dens-
ity of 200-400/well and subjected to lapatinib alone or a
combination of NH125 and lapatinib. The medium was
replaced every 3 days. Cells were stained with 1 %
methylene blue for 20 min after 10 days.
Western blot analysis
Western blot analysis was performed as described
previously [18]. The primary antibodies used were
eEF2K, phospho-eEF2 (Thr56), cleaved PARP (Asp214)
(D64E10), GAPDH, Phospho-p44/42 MAPK (Erk1/2)
(Thr202/Tyr204), Phospho-Akt (Ser473) (D9E) and
Phospho-Src family (Tyr416) (D49G4). All of the above-
mentioned antibodies were obtained from Cell Signaling
Technology (Danvers, MA, USA). Anti-hypoxia-inducible
factor (HIF)-1α antibody was purchased from BD Biosci-
ences (San Diego, CA, USA). The secondary antibodies
were horseradish peroxidase-conjugated goat anti-rabbit
or anti-mouse antibodies (1:2000, Santa Cruz, CA, USA).
Apoptosis detection assay
CNE-2, HONE-1 (8.0 × 104/well) and C666-1 cells (1.6 ×
105/well) were seeded into 6-well plates and treated with
different inhibitors for 48 h. Apoptosis was then de-
tected by the following procedures.
Flow cytometry analysis of Annexin V-APC/7-AAD staining
The Annexin V-APC/7-AAD Apoptosis Detection kit
(KGA1023-1026, KeyGEN, Nanjing, China) was used for
cell staining and flow cytometry (FC500; Beckman
Coulter, Brea, CA, USA) following the manufacturer’s in-
structions. Annexin V-APC-positive cells were considered
apoptotic regardless of the 7-AAD status. Experiments
Liu et al. BMC Cancer  (2016) 16:813 Page 2 of 8
were repeated three times, and the results are displayed as
histograms.
Flow cytometric analysis of cleaved PARP
The cells treated above were collected and blocked for
1 h in 5 % bovine serum albumin before staining with a
cleaved PARP (Asp214) (D64E10) antibody for 2 h at
37 °C. The cells were then stained with an anti-rabbit
IgG (H + L) F(ab′)2 fragment (Alexa Fluor® 555 Conju-
gate, Life Technologies, LA) antibody for 1 h followed
by washing with PBS. After washing, cells were analysed
by flow cytometry using the FACScan (BD Biosciences)
instrument.
RNA-mediated gene knockdown
Tumour cells in the logarithmic growth phase were
seeded in six-well plates at densities of 8.0 × 104/well
(CNE-2 and HONE-1 cells) and 1.6 × 105/well (C666-1
cells). The cells were grown overnight and then trans-
fected with small interfering RNA (siRNA), short hair-
pin RNA (shRNA) or control RNA, according to the
manufacturer's protocols.
siRNA transfection
eEF-2 kinase siRNA and control siRNA were synthesized
by Shanghai Gene-Pharma Co. (Shanghai, China).
shRNA transfection
Lentivirus-based shRNA targeting eEF-2 kinase and non-
targeting shRNA controls were obtained from Genechem
Co., Ltd (Shanghai, China).
Combination index analysis
The combination index (CI) of lapatinib plus NH125 was
analysed using CalcuSyn software (Biosoft, Ferguson, MO,
USA), which exploits mutually exclusive equations [19] to
determine the CI. A CI < 1 indicated synergism, a CI = 1
indicated additivity, and a CI > 1 indicated antagonism.
Statistical analysis
The experimental results are displayed as means ± stand-
ard deviation of the mean. GraphPad Prism 5 software
(GraphPad Software, San Diego, CA, USA) was used for
the statistical analyses. The Student’s t test (two tailed)
was used to compare groups, and a p-value < 0.05 was
considered statistically significant.
Results
Inhibition of eEF-2 kinase by NH125 sensitizes NPC cells
to lapatinib
Three NPC cell lines, including two poorly differentiated
cell lines, CNE-2 and HONE-1, and one Epstein-Barr
virus (EBV)-positive cell line, C666-1, were used to inves-
tigate the association between lapatinib sensitivity and
eEF-2 kinase status. Previous studies have shown that all
three cell lines used in this study co-express EGFR and
HER-2 to different degrees [1].
The CCK-8 assay was first applied to assess cell viabil-
ity after 48 h of lapatinib (0-10 μM) treatment with or
without 0.25 μmol/L NH125. As shown in Fig. 1a, cell
viability was reduced in a dose-dependent manner after
lapatinib exposure compared with control cells treated
with vehicle DMSO. The cytocidal activity of lapatinib
was markedly increased in the cells treated with NH125.
A crystal violet assay was used to further validate the
above results (Fig. 1b). A 10-day colony formation assay
was also performed, and the number of colonies was
dramatically reduced by lapatinib combined with NH125
treatment (Fig. 1c).
We next assessed whether eEF-2 kinase activation in-
hibits the NPC cell response to lapatinib. As shown in
Fig. 1d, higher eEF-2 kinase activity (increased phos-
phorylated eEF-2 levels) was induced by hypoxic con-
ditions. This suggests that hypoxia leads to a reduction
in the response to lapatinib, and that eEF-2 kinase acti-
vation suppresses the effect of lapatinib in NPC cells
(Fig. 1e).
The eEF-2 kinase inhibitor NH125 enhances lapatinib-
induced apoptosis in human NPC cells
To confirm and understand better the increased anti-
tumour action of lapatinib when combined with NH125,
annexin V-APC/7-AAD double staining was used to de-
tect apoptosis after treatment. Lapatinib combined with
NH125 significantly increased the population of Annexin
V-positive cells and therefore apoptosis (Fig. 2a).
Western blot analysis and flow cytometry were subse-
quently performed to analyse the levels of cleaved PARP,
a marker of apoptosis, in NPC cells in response to treat-
ment. There was a significant increase in the level of
cleaved PARP in cells treated with both lapatinib and
NH125, suggesting that NH125 increases apoptosis in
NPC cell lines (Fig. 2b and c).
Silencing of eEF-2 kinase by RNA interference increases
apoptosis in NPC cells treated with lapatinib
For further verification that eEF-2 kinase has an impact
on the sensitivity of NPC cells to lapatinib, we applied
RNA interference techniques to inhibit eEF-2 kinase
and assessed cell viability and apoptosis after lapatinib
treatment.
Transfecting NPC cells with an eEF-2 kinase siRNA
resulted in a significant decrease in cell viability com-
pared with controls (Fig. 3a). eEF-2 kinase knockdown
was also accompanied by an increase in apoptotic activ-
ity, as measured by Annexin V-APC/7-AAD double
staining (Fig. 3b).
Liu et al. BMC Cancer  (2016) 16:813 Page 3 of 8
A lentiviral vector carrying a shRNA against eEF-2
kinase was also constructed. The cytotoxicity of lapatinib
in NPC cells was greater after shRNA treatment com-
pared with empty vector controls (Fig. 3c). Fig. 3d shows
that the shRNA also enhanced apoptotic activity in re-
sponse to lapatinib. In addition, eEF-2 kinase inhibition
decreased colony formation in lapatinib-treated NPC
cells (Fig. 3e).
The synergistic effect of lapatinib and NH125
downregulates the Src/Erk signalling pathway
Since inhibition of eEF-2 kinase sensitizes NPC cells to
lapatinib, we next evaluated whether lapatinib and eEF-2
kinase inhibition have a synergistic effect. The CCK-8
assay showed that the rate of cell survival was signifi-
cantly decreased after treatment with lapatinib plus
NH125, compared with either treatment alone (Fig. 4a),
and the results of crystal violet staining further validated
these findings (Fig. 4b). Surprisingly, lapatinib and NH125
had a synergistic effect when treated in combination at a
lapatinib:NH125 ratio of 10:1 using lower doses (Fig. 4c).
After this synergistic effect was confirmed, several
common signalling pathways were investigated by
Western blot analysis. As shown in Fig. 4d, lapatinib
alone activated the AKT and ERK pathways in a dose-
dependent manner (increased phosphorylated AKT
and phosphorylated ERK1/2 levels), but it had no effect
on the Src pathway in NPC cells. Furthermore, sup-
pression of eEF-2 kinase activity by NH125 increased
the levels of cleaved PARP compared with lapatinib
alone. Co-treatment with NH125 and lapatinib de-
creased Src (decreased phosphorylated Src levels) and
ERK (decreased phosphorylated ERK1/2 levels) activ-
ities. However, NH125 had no effect on the AKT
Fig. 1 NH125 sensitizes NPC cells to lapatinib. a, b and c NPC cells were treated with lapatinib or DMSO for 48 h in the presence or absence of
0.25 μM NH125. a Cell viability was assessed by the CCK-8 assay. Results are expressed as means ± standard deviation. *, P<0.05;**, P<0.01 and ***,
P<0.001. b Inhibition of proliferation was measured by the crystal violet assay. HONE-1 cells are shown in a representative experiment. c Colony
formation was measured. CNE-2 cells are shown in a representative experiment d and e CNE-2 and HONE-1 cells were treated with lapatinib or
DMSO under normal or hypoxic (1 % O2) conditions for 48 h. d HIF-1α and phosphorylated eEF-2 levels were examined by Western blot analysis.
GAPDH was used as a loading control. e Cell viability was assessed by the CCK-8 assay
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activity (increased phosphorylated AKT levels) induced
by lapatinib.
These results indicate that downregulation of ERK and
Src signalling pathways is involved in the synergistic ef-
fect between NH125 and lapatinib.
Discussion
Lapatinib was approved for the treatment of breast
cancer due to the correlation between the EGFR and
HER-2 signaling and the poor prognosis. Moreover,
both EGFR and HER-2 are co-expressed in a high per-
centage of NPC patients [5, 6]. Therefore, several stud-
ies have examined the use of lapatinib in NPC cell
lines, but unfortunately the IC50 values have ranged
widely, from 500 nM to 16 μM [1]. Due to the high
IC50 values, unsatisfactory therapeutic outcomes have
been seen in several studies. In addition, despite good
clinical results, lapatinib resistance can result from a
variety of mechanisms. Therefore, strategies to aug-
ment the anti-tumour efficacy of lapatinib will render
this drug more beneficial to patients.
eEF-2 kinase, a critical negative modulator of protein
synthesis, has been reported to regulate the sensitivity
of cancer cells to several therapeutic drugs, including
MK-2206, deoxyglucose, velcade, curcumin, TNF-related
apoptosis-inducing ligand and temozolomide [13–17].
Due to the above results, we evaluated whether targeting
eEF-2 kinase affects the anti-tumour efficacy of lapatinib
in NPC cells. Similar to a previous study [1], phosphory-
lated EGFR and HER-2 were detected in CNE-2 and
HONE-1 cells, but only phosphorylated HER-2 was de-
tected in C666-1 cells. Thus, these three cell lines were
used to evaluate the effect of eEF-2 kinase on lapatinib
sensitivity.
Fig. 2 NH125 enhances lapatinib-induced apoptosis in NPC cells. a, b and c CNE-2 and HONE-1 cells were treated with lapatinib (0-5 μM) or
DMSO control for 48 h in the presence or absence of 0.25 μM NH125. a Annexin V-APC/7-AAD double staining was performed to detect
apoptotic activity. b Cleaved PARP was examined by Western blot analysis. GAPDH was used as a loading control. c Flow cytometry was
used to analyse cleaved PARP levels. Results are displayed as histograms. Each bar represents the mean ± standard deviation. *, P<0.05;**
and P<0.01
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Similar to previous studies, the results of this study
showed that inhibiting eEF-2 kinase through pharmaco-
logical or silencing techniques increased the anti-tumour
effect of lapatinib by augmenting apoptosis.
Next, we examined whether activating eEF-2 kinase
suppresses the cytocidal activity of lapatinib. Hypoxic
environments have been reported to induce eEF-2 activ-
ity [13], and we further showed that hypoxic conditions
decreased the anti-tumour effect of lapatinib by the
activation of eEF-2. These results suggest that eEF-2
kinase plays an important role in determining the
sensitivity of NPC cells to lapatinib, and that eEF-2
suppression enhances the cytotoxicity of lapatinib. In
contrast, the efficacy of lapatinib is reduced when eEF-2
is activated.
We infer that lapatinib and eEF-2 inhibition may have
a synergistic effect. Therefore, we investigated the
combination effect of NH125 and lapatinib. The results
showed that NH125 acts in synergy with lapatinib to
increase the cytocidal efficacy. However, the precise
molecular mechanism of this effect is unknown. Under
environmental or metabolic stress, eEF-2 kinase usually
acts as a positive regulator of autophagy [14, 20, 21].
Autophagy can promote both cell survival and cell death
depending on the conditions, and it acts to protect cells
and tissues from various stresses. Therefore, inhibiting
eEF-2 kinase-mediated protective autophagy could en-
hance cytotoxicity in response to various cancer treat-
ments [13, 17]. Under various stresses, lapatinib has
been shown to induce cell death autophagy, which was
Fig. 3 Silencing of eEF-2 kinase expression by RNA interference augments lapatinib-induced apoptosis in NPC cells. a and b NPC cells were transfected
with a non-targeting RNA (NT) or siRNA targeting eEF-2 kinase (eEF-2 K siRNA) followed by treatment with lapatinib or DMSO for 48 h. a Cell viability
was assessed by the CCK-8 assay. b Annexin V-APC/7-AAD double staining was performed to detect apoptotic activity. Results are displayed as
histograms. Each bar represents the mean ± standard deviation. *, P<0.05 and **, P<0.01. c, d and e NPC cells were transfected with an empty
vector control (Vector) or a shRNA targeting eEF-2 kinase (eEF-2 K shRNA) followed by treatment with lapatinib or DMSO control for 48 h. c Cell viability
was assessed by the CCK-8 assay. d Cleaved PARP and eEF-2 kinase levels were examined by Western blot analysis. GAPDH was used as a loading
control. Results are displayed as histograms. Each bar represents the mean ± standard deviation. *, P<0.05;**, P<0.01 and ***, P<0.001. e Colony
formation was measured. One representative experiment is shown (CNE-2 cells). Results are displayed as line charts to compare the decreasing trends
in colony number
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demonstrated as the type II programmed cell death in
hepatocellular carcinoma and chronic myelogenous
leukemia K562 cells [22, 23]. Lapatinib also induces
type II programmed cell death in NPC cells and we
have showed that autophagy is another important
mechanism of cell death acting in NPC cells.
To further explore the potential mechanisms, we de-
tected the phosphorylation levels of AKT, ERK and Src,
under the condition with or without NH125. There was a
significant reduction in the phosphorylation of both ERK
and Src, in the treatment with lapatinib and NH125, sug-
gesting that downregulation of ERK and Src signalling is
involved in this synergistic effect.
Together, these results suggest that the efficacy of lapati-
nib in NPC cells can be increased by inhibiting eEF-2 kin-
ase. Therefore, methods to decrease eEF-2 kinase activity
should be explored to enhance the efficacy of lapatinib
and other cancer treatments.
Conclusions
Combining lapatinib with NH125 had a synergistic effect
in NPC cells by downregulating the Src and Erk signalling
pathways and augmenting lapatinib-induced apoptosis.
These findings suggest that inhibition of eEF-2 may be a
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